EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 434-442 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 434 - 442
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025068
Published online 26 May 2025
  1. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017 ; 16 : 14–24. [CrossRef] [PubMed] [Google Scholar]
  2. Guessoum SB, Le Strat Y, Dubertret C, et al. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2020 ; 99 : 109862. [CrossRef] [PubMed] [Google Scholar]
  3. Mallet J, Guessoum SB, Tebeka S, et al. Self-evaluation of negative symptoms in adolescent and young adult first psychiatric episodes. Prog Neuropsychopharmacol Biol Psychiatry 2020 ; 103 : 109988. [CrossRef] [PubMed] [Google Scholar]
  4. Schmidt A, Cappucciati M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophr Bull 2017 ; 43 : 375–88. [PubMed] [Google Scholar]
  5. Bi R, Dong W, Zheng Z, et al. Altered motivation of effortful decision-making for self and others in subthreshold depression. Depress Anxiety 2022 ; 39 : 633–45. [CrossRef] [PubMed] [Google Scholar]
  6. McMakin DL, Olino TM, Porta G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry 2012 ; 51 : 404–11. [CrossRef] [PubMed] [Google Scholar]
  7. Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology and etiology. Schizophr Bull 2017 ; 43 : 712–9. [CrossRef] [PubMed] [Google Scholar]
  8. Fusar-Poli P, Tantardini M, De Simone S, et al. Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 2017 ; 40 : 65–75. [CrossRef] [PubMed] [Google Scholar]
  9. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull 2006 ; 70 : 312–21. [CrossRef] [PubMed] [Google Scholar]
  10. Pignon B, Peyre H, Ayrolles A, et al. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study. Epidemiol Psychiatr Sci 2022 ; 31 : e68. [CrossRef] [PubMed] [Google Scholar]
  11. Van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 2016 ; 15 : 118–24. [CrossRef] [PubMed] [Google Scholar]
  12. Foss-Feig JH, McPartland JC, Anticevic A, Wolf J. Re-conceptualizing ASD within a dimensional framework: positive, negative, and cognitive feature clusters. J Autism Dev Disord 2026 ; 46 : 342–51. [Google Scholar]
  13. Fusar-Poli, P. et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015 ; 41, 892–99. [CrossRef] [PubMed] [Google Scholar]
  14. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 2013 ; 47 : 783–90. [CrossRef] [PubMed] [Google Scholar]
  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington : APA, 2013. doi : 10.1176/appi.books.9780890425596. [Google Scholar]
  16. Fitzgerald HM, Shepherd J, Bailey H, et al. Treatment goals in schizophrenia: a real-world survey ofpatients, psychiatrists, and Caregivers in the United States, with an analysis of current treatment (long-acting injectable vs oral antipsychotics) and goal selection. Neuropsychiatr Dis Treat 2021 ; 17 : 3215–28. [CrossRef] [Google Scholar]
  17. Dollfus, S. Le déficit motivationnel dans la schizophrénie. Bull Acad Natl Med 2018 ; 202 : 115–26. [Google Scholar]
  18. Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry 2017 ; 44 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  19. Ihler HM, Lyngstad SH, Morch-Johnsen LE, et al. A transdiagnostic approach to negative symptoms: exploring factor structure and negative symptoms in bipolar disorders. Front Psychiatry 2023 ; 14 : 1136097. [CrossRef] [PubMed] [Google Scholar]
  20. Quattrone D, Di Forti M, Gayer-Anderson C, et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychol Med 2019 ; 49 ; 1378–91. [CrossRef] [PubMed] [Google Scholar]
  21. Lindenmayer JP, Bossie CA, Kujawa M, et al. Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology 2008 ; 41 : 264–70. [CrossRef] [PubMed] [Google Scholar]
  22. Trevisan DA, Foss-Feig JH, Naples AJ, et al. Autism spectrum disorder and schizophrenia are better differentiated by positive symptoms than negative symptoms. Front. Psychiatry 2020 ; 11 : 548. [CrossRef] [Google Scholar]
  23. Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms: a review of mechanisms, assessment and treatment. Schizophr Res 2017 ; 186 : 29–38. [CrossRef] [PubMed] [Google Scholar]
  24. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012 ; 33 ; 315–27. [CrossRef] [PubMed] [Google Scholar]
  25. Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart Br Card Soc 2010 ; 96 ; 1872–7. [CrossRef] [PubMed] [Google Scholar]
  26. Capuron L, Schroecksnadel S, Féart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011 ; 70 ; 175–82. [CrossRef] [PubMed] [Google Scholar]
  27. Zhao H, Zhang H, Liu S, et al. Association of peripheral blood levels of cytokines with autism spectrum disorder: a meta-analysis. Front Psychiatry 2021 ; 12 ; 670200. [CrossRef] [PubMed] [Google Scholar]
  28. Fond G, Mallet J, Urbach M, et al. Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs. BMJ Ment Health 2023 ; 26 ; e300771. [CrossRef] [Google Scholar]
  29. Lorentzen R, Nguyen TD, McGirr A, et al. The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. Schizophr Heidelb Ger 2022 ; 8 : 35. [CrossRef] [Google Scholar]
  30. Heeren A, Coussement C, Colon E. La stimulation transcrânienne à courant continu en psychiatrie : vers de nouvelles perspectives d’interventions. Med Sci (Paris) 2016 ; 32 : 752–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Fulford D, Marsch LA, Pratap A. Prescription digital therapeutics: an emerging treatment option for negative symptoms in schizophrenia. Biol Psychiatry 2024 ; 96 ; 659–65. [CrossRef] [PubMed] [Google Scholar]
  32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261–76. [CrossRef] [PubMed] [Google Scholar]
  33. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989 ; 155 : 49–52. [CrossRef] [Google Scholar]
  34. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res 1993 ; 27 : 253–8. [CrossRef] [PubMed] [Google Scholar]
  35. Kirkpatrick B, Strauss GP, Nguyen N, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull 2011 ; 37 : 300–5. [CrossRef] [PubMed] [Google Scholar]
  36. Kring AM, Gur RE, Blanchard JJ, et al. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry 2013 ; 170 : 165–72. [CrossRef] [PubMed] [Google Scholar]
  37. Llerena K, Park SG, McCarthy JM, et al. The motivation and pleasure scale-self-report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry 2013 ; 54 ; 568–74. [CrossRef] [PubMed] [Google Scholar]
  38. Mach C, Dollfus S. Symptômes négatifs de la schizophrénie : une revue des instruments d’évaluation. L’Encéphale 2016 ; 42 ; 165–71. [Google Scholar]
  39. Ike KGO, de Boer SF, Buwalda, B, et al. Social withdrawal: an initially adaptive behavior that becomes maladaptive when expressed excessively. Neurosci Biobehav Rev 2020 ; 116 : 251–67. [CrossRef] [PubMed] [Google Scholar]
  40. Ebrahimi A, Poursharifi H, Dolatshahi B, et al. The cognitive model of negative symptoms in schizophrenia: a hierarchical component model with PLS-SEM. Front Psychiatry 2021 ; 12 : 707291. [CrossRef] [PubMed] [Google Scholar]
  41. Nikiforuk A, Hołuj M, Kos T, et al. The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia. Neuropharmacology 2016 ; 105 : 351–60. [CrossRef] [PubMed] [Google Scholar]
  42. Lutsenko RV, Sydorenko AH, Bobyriov VM. Anhedonia at experimental models of chronic stress and its correction. Wiadomosci Lek Wars Pol 2017 ; 196070 : 745–50. [Google Scholar]
  43. Slaney CL, Hales CA, Robinson ESJ. Rat models of reward deficits in psychiatric disorders. Curr Opin Behav Sci 2018 ; 22 ; 136–42. [CrossRef] [PubMed] [Google Scholar]
  44. Bove M, Ike K, Eldering A, et al. The visible burrow system: a behavioral paradigm to assess sociability and social withdrawal in BTBR and C57BL/6J mice strains. Behav Brain Res 2018 ; 344 ; 9–19. [CrossRef] [PubMed] [Google Scholar]
  45. Sahin C, Doostdar N, Neill JC. Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model. Behav Brain Res 2016 ; 312 ; 93–101. [CrossRef] [PubMed] [Google Scholar]
  46. Millan M.J. Le récepteur dopaminergique D3 : nouvelle cible pour un traitement amélioré de la schizophrénie. Med Sci (Paris) 2005 ; 21 : 434–42. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.